The 340B Rebate Model Discussion Returns: HRSA Sends Proposal to the White
As HRSA’s proposed 340B rebate model moves to the White House Office of Management and Budget (OMB) for review, covered entities are once again preparing for what could become one of the most significant operational shifts in the modern 340B program. At the same time, organizations across healthcare are already experiencing the growing complexity of IRA Maximum Fair Price (MFP) requirements, delayed submissions, reconciliation challenges, and evolving manufacturer expectations. Those pressures are raising important questions about what the next phase of 340B operations may require. Join PharmaForce leaders Lynn Eschenbacher, Chief Pharmacy and Strategy Officer, and Anthony Velasquez, Chief Product Officer, for a timely discussion breaking down the latest developments surrounding updates around HRSA’s rebate model, the operational realities organizations are beginning to face, and what covered entities should be evaluating now to prepare. This session will explore: The latest White House and HRSA developments surrounding the 340B rebate model proposal Key themes emerging from more than 5,500 public comments submitted to HRSA What organizations have learned from early IRA MFP operational workflows and how those lessons may apply to emerging rebate models Submission, reconciliation, and reimbursement challenges providers may face under future rebate structures Why visibility, claims-level data, staffing models, and operational infrastructure are becoming increasingly critical What health systems should evaluate now around workflows, reporting, reconciliation readiness, and product-level impact analysis As manufacturers, regulators, and policymakers continue reshaping the 340B landscape, organizations will need more than policy awareness alone. They will need operational readiness, connected workflows, and the ability to quickly understand program impact at both the claims and product level. Whether you are actively preparing for future rebate model requirements or trying to better understand how IRA and MFP initiatives may influence 340B operations moving forward, this webinar will provide practical guidance, strategic perspective, and actionable considerations for 340B leaders navigating a rapidly changing environment. Presented By: Lynn Eschenbacher, Chief Pharmacy and Strategy Officer and Anthony Velasquez, Chief Product Officer.

340B Today: Policy Changes, Program Impact, and What Comes Next

340B Rebate Pilot Paused: What Covered Entities Need to Know Now

BMJ Best Practice & Comorbidities Manager in Action

Argentinien – Ägypten Highlights | Achtelfinale, FIFA WM 2026 | sportstudio

Lessons Learned Navigating State Level 340B Contract Pharmacy Protection Bills

Schweiz – Kolumbien Highlights | Achtelfinale, FIFA WM 2026 | sportstudio

340B Webinar - 5 Strategies to Reduce Impact of Manufacturer Blocks - PharmaForce

Trump slurring BADLY, STUNS leaders

TPA Membership Meeting 06 26 26

Referral Capture Under the 340B Rebate Model: Preparing for Jan 1

NEPRO Innovation Supplier Event: catch up on-demand

Billionaire's WARNING: I'm SELLING. The Crash Is Already Here!

Participant Engagement Committee Meeting June 2026

The Mitochondria Doctor: This Reverses Gray Hair, Makes You Feel Young Again & Fixes Disease!

Washington Week with The Atlantic full episode, July 3, 2026

Misuse and Sanctions of AI in the Practice of Law as an Employer

Webinar: From Genomic Testing Readiness to Rare Disease System Readiness (June 2026)

LIVE: Meidas Host TESTIFIES Before CONGRESS

340B Rebate Model: 8 Plans Going Live Jan 1 2026

